,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-12-05 01:58:00,The Zacks Research Daily presents the best research output of our analyst team.,0.6325156092643738,0.012341027148067951,0.35514333844184875,positive,0.6201745867729187
1,2017-12-05 01:58:00,"Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Boeing (BA) and Merck (MRK).",0.04180389270186424,0.00778130954131484,0.950414776802063,neutral,0.034022584557533264
2,2017-12-05 01:58:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
3,2017-12-05 01:58:00,"You can see all of today's research reports here >>>

Buy-rated Home Depot 's shares have gained +37.9% year to date, compared with the +31.5% gain of the Zacks Retail Building Products industry, backed by its five-year long trend of beating earnings estimates.",0.9548047184944153,0.02757764793932438,0.017617598176002502,positive,0.9272270798683167
4,2017-12-05 01:58:00,"The company delivered bottom-line beat in third-quarter fiscal 2017, while sales topped estimates for the fifth straight quarter.",0.9310442209243774,0.028892597183585167,0.04006313532590866,positive,0.9021516442298889
5,2017-12-05 01:58:00,"Results gained from strength in core business as well as relentless focus on affording innovative products, boosting interconnected customer experience and driving productivity.",0.9371642470359802,0.014141994528472424,0.04869364947080612,positive,0.9230222702026367
6,2017-12-05 01:58:00,Steady housing market recovery and strong customer demand also remained tailwinds.,0.41334089636802673,0.4791700541973114,0.10748894512653351,negative,-0.06582915782928467
7,2017-12-05 01:58:00,"While hurricane-related activities aided comps growth, gross margins on such sales were significantly below average.",0.020050186663866043,0.9636198878288269,0.016329914331436157,negative,-0.9435697197914124
8,2017-12-05 01:58:00,"This led to a decline in gross margin, which is likely to continue in fiscal 2017.",0.018560631200671196,0.968575656414032,0.012863771989941597,negative,-0.9500150084495544
9,2017-12-05 01:58:00,"Moreover, competition from online retailers may impact performance.",0.03194781765341759,0.7816116809844971,0.1864406019449234,negative,-0.7496638894081116
10,2017-12-05 01:58:00,(You can read the full research report on Home Depot here >>> ).,0.012610534206032753,0.013505421578884125,0.973884105682373,neutral,-0.0008948873728513718
11,2017-12-05 01:58:00,"Shares of Boeing have surged +78.6% over the past year, outperforming the Zacks Aerospace & Defense sector, which gained +39.2% during the same time period.",0.9494842886924744,0.03011908568441868,0.020396742969751358,positive,0.9193652272224426
12,2017-12-05 01:58:00,"Notably, Boeing is the largest aircraft manufacturer in the world in terms of revenue, orders and deliveries, and one of the largest aerospace and defense contractors.",0.4596852660179138,0.010354508645832539,0.5299602150917053,neutral,0.44933074712753296
13,2017-12-05 01:58:00,"In this regard, the company's 20-year market outlook forecasts commercial jetliner demand to increase by 3.6%.",0.9528864026069641,0.015554811805486679,0.03155876696109772,positive,0.9373316168785095
14,2017-12-05 01:58:00,"Yet, this aerospace company continues to face challenges from order cancellations, stiff competition as well as falling delivery numbers.",0.02643805369734764,0.945465087890625,0.02809685468673706,negative,-0.9190270304679871
15,2017-12-05 01:58:00,"Furthermore, Boeing's 787 Dreamliner's deferred production cost remains a cause of concern.",0.022067919373512268,0.9182311296463013,0.05970092862844467,negative,-0.8961632251739502
16,2017-12-05 01:58:00,(You can read the full research report on Boeing here >>> ).,0.01499143522232771,0.012919407337903976,0.9720891118049622,neutral,0.0020720278844237328
17,2017-12-05 01:58:00,"Merck 's shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the last year, losing -6.8% versus +18.5%, as the company has suffered some notable pipeline setbacks this year.",0.027090594172477722,0.9628385901451111,0.01007088739424944,negative,-0.9357479810714722
18,2017-12-05 01:58:00,"Merck enjoys a diversified business across branded drugs, vaccines and animal health.",0.22747384011745453,0.0060293059796094894,0.7664968371391296,neutral,0.2214445322751999
19,2017-12-05 01:58:00,Merck has made significant progress with its pipeline and is working on bringing new products to the market.,0.9167266488075256,0.012010951526463032,0.07126236706972122,positive,0.9047157168388367
20,2017-12-05 01:58:00,New products like Keytruda and Zepatier should continue to contribute meaningfully to the top line.,0.9212912917137146,0.012524315156042576,0.06618444621562958,positive,0.9087669849395752
21,2017-12-05 01:58:00,Keytruda is gaining strong momentum from new indication of first-line lung cancer.,0.9365800023078918,0.015606309287250042,0.047813668847084045,positive,0.9209737181663513
22,2017-12-05 01:58:00,The Keytruda development program also significantly advanced this year with several key regulatory approvals.,0.940843403339386,0.01615375280380249,0.043002791702747345,positive,0.9246896505355835
23,2017-12-05 01:58:00,"Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line.",0.8275777697563171,0.013668387196958065,0.1587538719177246,positive,0.8139094114303589
24,2017-12-05 01:58:00,"However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line.",0.09528374671936035,0.08432639390230179,0.8203898668289185,neutral,0.010957352817058563
25,2017-12-05 01:58:00,Rising competition in the immuno-oncology market is also a significant concern.,0.055177539587020874,0.3132378160953522,0.631584644317627,neutral,-0.2580602765083313
26,2017-12-05 01:58:00,(You can read the full research report on Merck here >>> ).,0.012997591868042946,0.011902625672519207,0.9750998020172119,neutral,0.0010949661955237389
27,2017-12-05 01:58:00,"Other noteworthy reports we are featuring today include Sinopec (SNP), Allstate (ALL) and Illumina (ILMN).",0.051218513399362564,0.0050321961753070354,0.9437493085861206,neutral,0.04618631675839424
28,2017-12-05 01:58:00,Looking for Stocks with Skyrocketing Upside?,0.09469357132911682,0.09826507419347763,0.807041347026825,neutral,-0.0035715028643608093
29,2017-12-05 01:58:00,Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.,0.41462862491607666,0.01087752915918827,0.5744938254356384,neutral,0.40375110507011414
30,2017-12-05 01:58:00,"Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021.",0.8838319182395935,0.03136736899614334,0.08480073511600494,positive,0.8524645566940308
31,2017-12-05 01:58:00,"Early investors stand to make a killing, but you have to be ready to act and know just where to look.",0.19955629110336304,0.018484661355614662,0.781959056854248,neutral,0.18107162415981293
32,2017-12-05 01:58:00,"See the pot trades we're targeting>>

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings.",0.08856207132339478,0.007175061851739883,0.904262900352478,neutral,0.08138701319694519
33,2017-12-05 01:58:00,He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Preview reports.,0.025165576487779617,0.008906112052500248,0.9659282565116882,neutral,0.016259465366601944
34,2017-12-05 01:58:00,"If you want an email notification each time Sheraz publishes a new article, please click here>>>

The Zacks analyst values Sinopec's discoveries - the Shengli field and Junggar Basin, which will support long-term production

Per the Zacks analyst, a balanced organic and inorganic growth model, a lean and flexible cost structure, and an agile and entrepreneurial management team remain key growth drivers for Amphenol.",0.8164229393005371,0.010931579396128654,0.1726454794406891,positive,0.8054913878440857
35,2017-12-05 01:58:00,"Per the Zacks analyst, Big Lots' furniture and soft home categories will continue to drive sales in coming quarters.",0.7270240187644958,0.012918781489133835,0.2600572109222412,positive,0.7141052484512329
36,2017-12-05 01:58:00,"Per the Zacks analyst initiatives such as pricing discipline and strong claims management have led to premium growth at both its segments, but high weather related losses hurt margins.",0.09005018323659897,0.8918673992156982,0.01808236911892891,negative,-0.8018172383308411
37,2017-12-05 01:58:00,"Life Science Assets to Drive Growth for Alexandria (ARE)

Per the Zacks Analyst, strong fundamentals in the life-science industry has driven demand for Alexandria's properties.",0.9438796043395996,0.01478308904916048,0.04133730009198189,positive,0.929096519947052
38,2017-12-05 01:58:00,"Per the Zacks analyst, Universal Technical's enrollments have been sluggish for several quarters now, which is marring growth prospects.",0.020993277430534363,0.9547669291496277,0.02423976920545101,negative,-0.9337736368179321
39,2017-12-05 01:58:00,"Per the Zacks analyst, an optimum mix of highly engineered and niche-oriented products is helping Roper to gain market share.",0.9389721155166626,0.013878642581403255,0.04714920371770859,positive,0.9250934720039368
40,2017-12-05 01:58:00,"The Zacks analyst thinks Newmont should gain from its efforts to boost production performance, de-lever its balance sheet and improve operational efficiency.",0.9529294967651367,0.017454389482736588,0.029616190120577812,positive,0.9354751110076904
41,2017-12-05 01:58:00,"The Zacks analyst expects Illumina to maintain its growth momentum on continued uptake of sequencing consumables, instruments and microarray portfolios.",0.949251651763916,0.013824047520756721,0.03692431002855301,positive,0.9354276061058044
42,2017-12-05 01:58:00,Recent strategic pacts should add value.,0.758394718170166,0.01343184057623148,0.2281733900308609,positive,0.7449628710746765
43,2017-12-05 01:58:00,"According to the Zacks analyst, Red Hat is benefiting from strong deal wins, improving recurring revenues and cross-selling of cloud-based technology.",0.9580664038658142,0.01871354505419731,0.023220090195536613,positive,0.9393528699874878
44,2017-12-05 01:58:00,Expanding partner base is also positive.,0.9345977306365967,0.01660575345158577,0.04879649356007576,positive,0.9179919958114624
45,2017-12-05 01:58:00,"Per the Zacks analyst, mounting competition in the semiconductor space and resultant pricing pressure will continue to weigh on Semtech's margins and profitability.",0.040382880717515945,0.8958536386489868,0.06376348435878754,negative,-0.8554707765579224
46,2017-12-05 01:58:00,"The Zacks analyst is pessimistic about Altice USA's operations in a consumer and technology-driven market, which is highly dependent on rapidly changing businesses and consumer choices.",0.021753711625933647,0.9446178674697876,0.033628493547439575,negative,-0.9228641390800476
47,2017-12-05 01:58:00,"Jack in the Box (JACK) Affected By Declining Comps at Qdoba

Per the Zacks analyst, persistent lower comps at Jack in the Box's Qdoba brand is significantly hurting the company's overall sales amid an already challenging restaurant environment.",0.021482326090335846,0.9685503840446472,0.009967322461307049,negative,-0.9470680356025696
48,2017-12-05 01:58:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
49,2017-12-05 01:58:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
50,2017-12-05 01:58:00,"Click to get this free report

To read this article on Zacks.com click here.",0.02068457007408142,0.033159855753183365,0.9461556077003479,neutral,-0.012475285679101944
51,2017-12-05 01:58:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
